Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $0.4352W HIGH $3.27
Volume
199.71 K
Value Traded
20.03 K
Short % Float
5.64%
-15.51%Week
-11.06%1 Month
-36.8%3 Month
-67.55%6 Month
-99.39%5 Year
-100%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
7.38 M
EPS (TTM)
-1.40
P/E Ratio
-
Ent. Value
2.37 M
Total Shares
15.37 M
Float Shares
10.86 M
Insiders
29.34%
Institutions
27.10%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
| Catalyst | Drug / Treatment | Stage | Prob. of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | Small Molecule | Oncology | - |
PoA blends historical approval base rates, trial design score and FDA review track record.
TRAW Catalyst Timeline
Dated clinical, regulatory and corporate events for Traws Pharma, Inc.
Catalyst Timeline
Dated clinical, regulatory & corporate events for Traws Pharma, Inc.
503Total events
5Upcoming
97Tier-1 (high impact)
2013 to 2027Coverage
Upcoming catalysts 2
Event history 50
◆MHRA Milestonetivoxavir marboxilEx-US Regulatory
Updated toxicology data package resubmission to MHRA for TXM Phase 2a Challenge study
seasonal influenza prophylaxissource ↗
◆Other Regulator Milestonetivoxavir marboxilEx-US Regulatory
MHRA resubmission of tivoxavir marboxil toxicology package expected at end of Q3 2026
influenzasource ↗
▼MHRA Milestonetivoxavir marboxilEx-US Regulatory
MHRA negative review of tivoxavir marboxil Phase 2a challenge study
influenzasource ↗
▼Trial Pausedtivoxavir marboxilTrial
Phase 2a human influenza challenge study deferred
influenzasource ↗
●Trial Initiationtivoxavir marboxilTrial
Seasonal influenza virus prophylaxis Challenge Study at hVIVO
Seasonal Influenza (prophylaxis)source ↗
◆Preclinical PoCPreclinical
Advancing non-clinical development in validated animal models of Hantavirus and Ebola
Hantavirus, Ebola, Lassasource ↗
◆Manufacturing MilestoneCMC / Inspection
Scaling up chemical development and manufacturing infrastructure for immediate supply
Hantavirus, Ebola, Lassasource ↗
◆Other Regulator MilestoneEx-US Regulatory
Planned interactions with CDC, ongoing with NAFDAC and AMA to fast-track development
Hantavirus, Ebola, Lassasource ↗
◆Development Candidate NominationPreclinical
Plans to advance potential clinical candidates for hantavirus treatment
hantavirus infectionssource ↗
▲Topline ReadoutRatutrelvirClinical Data
Topline Phase 2a data for ratutrelvir reported; final analysis underway
COVID-19source ↗
◆Trial Initiationtivoxavir marboxilTrial
Initiation of human challenge trial as once-monthly prophylactic
influenza prophylaxissource ↗
●Equity OfferingCorporate
April 2026 private placement completed with $10.0 million upfront proceeds
◆FDA Feedback Receivedtivoxavir marboxilFDA Meeting
FDA intends to communicate concerns and mitigation steps by March 16, 2026
avian influenzasource ↗
▲Full ResultsRatutrelvirClinical Data
Completed analysis of Phase 2 study of ratutrelvir vs PAXLOVID in COVID-19 patients
COVID-19source ↗
▼Clinical Hold Placedtivoxavir marboxilIND
FDA placed US IND for tivoxavir marboxil on clinical hold due to mutagenicity data concerns
avian influenzasource ↗
●IND Submissiontivoxavir marboxilIND
PK study of compressed tivoxavir marboxil tablets submitted under open IND in Australia
seasonal influenza prophylaxissource ↗
▲Enrollment CompleteRatutrelvirTrial
Completed enrollment in Phase 2 study of ratutrelvir vs PAXLOVID in mild-to-moderate COVID-19 patients
COVID-19source ↗
▲Interim AnalysisRatutrelvirTrial
Updated interim analysis of ratutrelvir Phase 2 study vs PAXLOVID
COVID-19source ↗
◆Full ResultsRatutrelvirClinical Data
Final data analysis of Phase 2 study of ratutrelvir
COVID-19source ↗
▲Trial Initiationtivoxavir marboxilTrial
Initiation of Phase 1 Bridging Study in Australia
influenza prophylaxissource ↗
◆Topline ReadoutRatutrelvirClinical Data
Expected top line data for ratutrelvir Phase 2 studies by year end
Acute and Long COVIDsource ↗
▲Interim AnalysisRatutrelvirTrial
Interim data from Phase 2 study of ratutrelvir vs PAXLOVID in mild-to-moderate COVID-19
COVID-19source ↗
▲First Patient DosedRatutrelvirTrial
First patient dosed in Phase 2 non-inferiority trial vs PAXLOVID
COVID-19source ↗
▲Management ChangeCorporate
Iain Dukes and Charles Parker appointed as permanent CEO and CFO, respectively
▲Partnership / LicenseCorporate
Asset Purchase Agreement with Viriom, Inc. for pyrrolidine antiviral compound IP
▲Trial InitiationRatutrelvirTrial
Phase 2 non-inferiority trial of ratutrelvir vs PAXLOVID in newly diagnosed COVID subjects
COVID-19source ↗
●Type D Meetingtivoxavir marboxilFDA Meeting
FDA reaffirmed clinical trial data as registrational path for bird flu therapeutics
bird flusource ↗
▲Trial Initiationtivoxavir marboxilTrial
Phase 2 bird flu/seasonal flu protocol approved by Australian and South Korean regulators
bird flu and seasonal flusource ↗
▲Trial InitiationRatutrelvirTrial
Submitted HREC study will enable initiation of Phase 2 studies of ratutrelvir
COVID-19source ↗
◆Partnership / LicenseCorporate
Actively seeking development and commercialization partners for rigosertib and narazaciclib
oncologysource ↗
◆Trial InitiationRatutrelvirTrial
Phase 2 study of ratutrelvir planned to begin soon in Southern Hemisphere
COVID-19source ↗
●IND Submissiontivoxavir marboxilIND
Phase 2 protocol submitted to HREC for tivoxavir marboxil combined seasonal and bird flu study
seasonal influenza and H5N1 bird flusource ↗
●Type D Meetingtivoxavir marboxilFDA Meeting
Briefing documents submitted to FDA for Type D meeting on accelerated approval path for TXM in bird flu
H5N1 bird flusource ↗
●IND SubmissionRatutrelvirIND
HREC Phase 2 protocol submitted for ratutrelvir in acute COVID
acute COVID including PAXLOVID-ineligible subjects with assessments of rebound and Long COVIDsource ↗
▲Full ResultsRigosertibFiledClinical Data
Publication of clinical efficacy data for rigosertib in RDEB SCC patients in British Journal of Dermatology
RDEB-associated SCCsource ↗
Past FDA Catalysts and PDUFA Decisions
How TRAW actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2025-12-31 | Ratutrelvir | Phase 2 topline data readout | Phase 2 |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
D32 / 100
Pipeline Score
$4M
Pipeline Value
Overvalued
Valuation Signal
5
Drugs Scored
0.5x
rNPV / MCap
Top 64%
Micro Cap(rank 421 of 658)
Percentile Rank
Traws Pharma, Inc. faces pipeline headwinds (32/100), with $1.3B risk-adjusted pipeline value, led by Rigosertib in Non-small Cell Lung Cancer (Phase 1), across $74B in total addressable markets, but cash runway is a concern.
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Rigosertib Small moleculeCompletedNCT01926587 | Myelodysplastic Syndrome | Phase 3 | COMPLETED | 239 | Feb 16, 2021 |
Clinical Trial Results
Readouts, endpoints and source filings for every TRAW program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| ratutrelvir | COVID-19 | Phase 2 | 2026-01-27 | 90-patient, open-label Phase 2 study; ratutrelvir 600 mg orally, once daily for 10 days; PAXLOVID® administered as nirmatrelvir 300 mg twice daily plus 100 mg ritonavir twice daily for 5 daysRead More | Traws Pharma Completes Enrollment of Ratutrelvir Clinical Study in PAXLOVID®-Eligible and Ineligible COVID-19 Patients; Announces Plans for Added Indication for Tivoxavir Marboxil as a Prophylactic Treatment for Seasonal InfluenzaRead More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Dukes Iain D.Director, Officer (Chief Executive Officer) | Grant/Award | 274,000 274,000 held | $0.00 | 07/09/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in TRAW
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| ORBIMED ADVISORS LLC | 0 % | 1.01 M | 1.20 M | 98.71% ( 597.73 K) |
TRAW Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How TRAW ranks across every disease it competes in
Competitive Position is a premium feature
See how TRAW ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialTRAW News
TRAW▼ -5.4%on this news
Traws Pharma Reports Q2 2026 Financial Results and Provides Business Highlights
Traws Pharma reported its Q2 2026 financial results, highlighting progress on tivoxavir marboxil, which is set for MHRA resubmission in Q3 2026. The company completed a financing round that could provide up to $50 million, contingent on achieving specific milestones. However, the FDA has placed a clinical hold on the drug's U.S. IND due to concerns with the toxicology data package.
Read more →TRAWTraws Pharma Provides Updated Guidance on Influenza Prophylaxis Program
Traws Pharma has announced the development of an updated toxicology data package for tivoxavir marboxil (TXM) in response to the UK's MHRA requirements. This package is intended to support a Phase 2a influenza Challenge study in healthy volunteers, with resubmission expected in Q3 2026. TXM has demonstrated efficacy against various influenza strains, highlighting its potential as an oral prophylactic agent.
Read more →TRAW▼ -41%on this news
Traws Pharma Provides Regulatory Update on Influenza Program
Traws Pharma announced a deferral of its Phase 2a human influenza challenge study for tivoxavir marboxil due to negative feedback from the UK's MHRA. Despite this setback, the company emphasizes the potential of its antiviral candidates and maintains a commitment to developing long-acting influenza treatments. The program remains a priority, especially for vulnerable populations.
Read more →TRAWTraws Pharma Announces Antiviral Program Targeting Ongoing Hantavirus and Ebola Virus Disease Outbreaks
Traws Pharma has announced a new antiviral program aimed at addressing the ongoing outbreaks of Hantavirus and Ebola Virus Disease. The proprietary combination agent utilizes a dual-strike mechanism to effectively lower the necessary drug concentration for treatment. The company is collaborating with the CDC and the NAFDAC to expedite clinical development and prepare for swift manufacturing and distribution. This initiative reflects Traws Pharma's commitment to combatting critical global viral threats with innovative solutions.
Read more →TRAW▲ +15.3%on this news
Traws Pharma Provides Business Highlights and Reports Q1 2026 Financial Results
Traws Pharma reported significant business highlights and financial results for Q1 2026, including a successful private financing of up to $60 million. The company is advancing its lead program, tivoxavir marboxil, towards a human influenza challenge trial and is also developing treatments for hantavirus infections. However, the FDA has placed a clinical hold on the U.S. IND for TXM due to toxicology concerns.
Read more →TRAW▲ +28.2%on this news
Traws Pharma to Advance Potential Clinical Candidates for the Treatment of Hantavirus Infections
Traws Pharma is progressing with clinical candidates aimed at treating Hantavirus infections, a serious health threat with a high fatality rate. The company is leveraging its antiviral drug development expertise to address this urgent need, especially given the lack of approved treatments. Their strategy includes utilizing existing antiviral assets and proprietary chemical libraries to identify effective therapies.
Read more →TRAWTraws Pharma Reports Full Year 2025 Results and Provides Business Highlights
Traws Pharma reported its financial results for 2025, highlighting advancements in its investigational programs, including tivoxavir marboxil for influenza and ratutrelvir for COVID-19. The company secured $60 million in private financing, expected to support operations into Q1 2027. Positive Phase 2a data for ratutrelvir indicates a differentiated profile compared to existing treatments. However, the company is facing a clinical hold from the FDA on its TXM program.
Read more →TRAW▼ -22.6%on this newsshared move
Traws Pharma Announces Up to $60 Million Private Placement Financing
Traws Pharma has announced a successful private placement financing of up to $60 million, led by Sirenia Capital Management. The initial $10 million will support a human challenge trial for tivoxavir marboxil in the UK, with additional milestone-based proceeds potentially bringing the total to $60 million. The financing positions Traws to advance its influenza program while maintaining access to further capital.
Read more →TRAW▼ -20.3%on this news
Traws Pharma Completes Analysis of Ratutrelvir Clinical Study in PAXLOVID -Eligible and Ineligible COVID-19 Patients and Provides Updates for Additional Indication for Tivoxavir Marboxil as a Prophylactic Treatment for Seasonal Influenza
Traws Pharma has completed an analysis of its Phase 2 clinical study for ratutrelvir, demonstrating favorable outcomes against PAXLOVID for COVID-19 patients, including fewer adverse events and quicker symptom resolution. The company is also advancing its investigational compound, Tivoxavir Marboxil, which showed significant pre-clinical promise as a prophylactic treatment for seasonal influenza. However, the FDA has placed this compound's IND application on clinical hold due to concerns regarding mutagenicity. Traws Pharma is currently addressing these concerns to continue its clinical development plan.
Read more →TRAWTraws Pharma Completes Enrollment of Ratutrelvir Clinical Study in PAXLOVID®-Eligible and Ineligible COVID-19 Patients; Announces Plans for Added Indication for Tivoxavir Marboxil as a Prophylactic Treatment for Seasonal Influenza
Traws Pharma has completed enrollment in a Phase 2 study of ratutrelvir, an oral COVID-19 treatment, which shows promise in patients unable to take PAXLOVID. The study indicates ratutrelvir has a favorable safety profile and may help reduce the risk of Long COVID. Additionally, Traws is advancing tivoxavir marboxil for influenza prophylaxis, with a challenge study planned for June 2026.
Read more →TRAW▲ +26.8%on this news· ran to +59% by day 3
Traws Pharma Files Tivoxavir Marboxil Investigational New Drug (IND) Application for Influenza Therapy, and Provides Updated Results from the Ongoing Clinical Study of Ratutrelvir in PAXLOVID®-Eligible and Ineligible COVID-19 Patients
Traws Pharma has filed a U.S. IND application for tivoxavir marboxil, a potential treatment for influenza, marking a key step for its inclusion in the national stockpile. The company also reported updated interim results for ratutrelvir, an investigational COVID-19 therapy, which demonstrated a favorable safety and efficacy profile compared to PAXLOVID. The study aims to address treatment gaps for patients ineligible for existing therapies.
Read more →TRAW▼ -36.4%on this news
Traws Pharma Reports Positive Interim Clinical Data with Ratutrelvir Versus PAXLOVID™, Shows Activity in PAXLOVID-Ineligible COVID-19 Patients
Traws Pharma has reported positive interim clinical data for ratutrelvir, an investigational COVID-19 treatment, showing a favorable profile compared to PAXLOVID™. The drug demonstrated efficacy in patients who are ineligible for PAXLOVID™, with fewer adverse events and no viral rebounds observed. The final data analysis is expected in January 2026.
Read more →TRAW▼ -17.3%on this news
Traws Pharma Reports Third Quarter 2025 Results and Business Highlights
Traws Pharma reported its third-quarter results for 2025, highlighting progress in Phase 2 studies for ratutrelvir, an investigational treatment for COVID-19. The company acquired significant intellectual property and achieved cost reductions. However, it faced a net loss of $4.0 million and a drop in revenue to zero compared to the previous year.
Read more →TRAWTraws Pharma Doses First Patient with Ratutrelvir in Phase 2 COVID Studies, Expects Results by Year-End 2025
Traws Pharma has commenced dosing in a Phase 2 study to evaluate ratutrelvir, a ritonavir-free antiviral treatment for COVID-19. This trial aims to compare its safety and efficacy against PAXLOVID, focusing on disease rebound and Long COVID. A separate trial will assess ratutrelvir in patients ineligible for PAXLOVID. Results from both studies are anticipated by the end of 2025.
Read more →TRAWTraws Pharma Adds John Leaman, MD, as Independent Director and Formalizes Appointments of Two Key Executives
Traws Pharma has appointed Dr. John Leaman as an independent director and confirmed the roles of Iain Dukes and Charles Parker as CEO and CFO, respectively. This move is aimed at strengthening the company's governance and leadership as it advances its lead antiviral candidate, ratutrelvir, for COVID-19. The company is focused on developing novel therapies targeting respiratory viral diseases.
Read more →TRAW▼ -6%on this news
Traws Pharma Receives Approval to Proceed with Phase 2 COVID Studies with Ratutrelvir, Expects Results by Year-End 2025
Traws Pharma has received approval to initiate Phase 2 studies for ratutrelvir, a ritonavir-free COVID-19 treatment. The trials will compare ratutrelvir's efficacy against PAXLOVID and assess its safety in patients ineligible for PAXLOVID. Results are expected by the end of 2025, with potential implications for vulnerable populations and the broader COVID treatment market.
Read more →TRAWTraws Pharma Reports Second Quarter 2025 Results and Business Highlights
Traws Pharma has reported its Q2 2025 financial results and highlighted advancements in its antiviral programs targeting respiratory viruses, including ratutrelvir for COVID-19 and influenzavirus. The company is preparing to initiate Phase 2 trials for ratutrelvir in newly diagnosed COVID patients, while also receiving regulatory approvals for its flu-related studies. Despite recent progress, Traws faces recruitment challenges for its bird flu study and reported a notable net loss for the quarter. The overall sentiment reflects optimism regarding their novel therapies amid a public health crisis.
Read more →TRAWTraws Pharma to Report Second Quarter 2025 Financial Results on Thursday, August 14, 2025
Traws Pharma, Inc. will host a conference call on August 14, 2025, to discuss its second quarter financial results and recent business developments. The company focuses on developing antiviral therapies for respiratory viral diseases, including COVID-19 and seasonal influenza. Traws is also seeking partners for its oncology programs.
Read more →TRAWTraws Pharma Advances Antiviral Pipeline with Multiple Regulatory Submissions
Traws Pharma has submitted multiple regulatory documents to advance its antiviral pipeline, including a Phase 2 study for tivoxavir marboxil (TXM) targeting seasonal and bird flu. Additionally, a Phase 2 study for ratutrelvir in newly diagnosed COVID patients has been proposed. The company is seeking accelerated approval for TXM through discussions with the FDA.
Read more →About Traws Pharma, Inc.
Headquarters12 PENNS TRAIL, NEWTOWN, PA, 18940
BIOPHARMAWATCH ELITE PLUS
Trade the next TRAW catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime